Fig. 2. Effects of AZD4785 on proliferation and MAPK pathway signaling in KRAS mutant and wild-type cancer cells in vitro. Effects of AZD4785 on proliferation.

Slides:

Advertisements

Similar presentations

Productive Replication of Ebola Virus Is Regulated by the c-Abl1 Tyrosine Kinase by Mayra García, Arik Cooper, Wei Shi, William Bornmann, Ricardo Carrion,

Advertisements

SCLCs and LCNECs are sensitive to PARP inhibition in vitro.

Differentiation of AZD4785 from MAPK pathway inhibitors in vitro

Fig. 1. Potent and selective down-regulation of KRAS mRNA and protein by AZD4785 in vitro and in vivo. Potent and selective down-regulation of KRAS mRNA.

Fig. 3. Cytokines trigger proliferation and block differentiation of perivascular adipocytes. Cytokines trigger proliferation and block differentiation.

Fig. 1. The cell-intrinsic fibroblast circadian proteome contains numerous cytoskeletal regulators. The cell-intrinsic fibroblast circadian proteome contains.

Fig. 5. Circulating PPi concentration does not correlate with severity of calcification phenotype in mice. Circulating PPi concentration does not correlate.

A FOXO3a-BIM cascade mediates sensitivity to PARP and MEK inhibition

BET inhibition and depletion repress the expression of BRCA1 and RAD51

Fig. 8. Gene and protein changes in ALK-dependent STING pathways in human sepsis. Gene and protein changes in ALK-dependent STING pathways in human sepsis.

β-ARs signal cooperatively with mutant EGFR and inactivate LKB1

Fig. 2. In vitro profiling of tEV markers on cell line–derived EVs.

Fig. 6. Treatment with a DLK inhibitor is neuroprotective and reverses stress-induced gene expression changes. Treatment with a DLK inhibitor is neuroprotective.

Fig. 4. Functional annotation of VUS in EGFR.

Fig. 2. Mutant KRAS mediates resistance to PARPi and sensitivity to PARPi and MEKi Mutant KRAS mediates resistance to PARPi and sensitivity to PARPi and.

Synergistic effect of S63845 with lapatinib, trastuzumab, or docetaxel

Fig. 6. Pathway analysis of CMLD

Fig. 6 Bimodal treatment results in reduced tinnitus loudness and reduced TFI scores in human patients. Bimodal treatment results in reduced tinnitus loudness.

Fig. 2. GPC3 expression in normal and tumor tissues.

Bio-AMS enhances the activity of rifampicin and ethambutol in vitro

Fig. 1 Chemical inactivation of BPL kills Mtb and prevents growth in mouse macrophages. Chemical inactivation of BPL kills Mtb and prevents growth in mouse.

Fig. 4. Antitumor efficacy of ERY974 against various cancer types.

Fig. 4. MATE1 transcription in RCC.

Fig. 4 Nanocages captured multiple TB-related analytes.

Fig. 4. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in vivo. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in.

Fig. 4. Actin polymerization rhythms are required for circadian regulation of adhesion and wound-healing efficacy by fibroblasts. Actin polymerization.

Fig. 3. AD80 is active against gatekeeper mutant RETV804M cells.

Fig. 2. Pathways differentially regulated in patients with early Lyme disease and STARI. Pathways differentially regulated in patients with early Lyme.

Fig. 2. STUB1 destabilizes and ubiquitinates TF and mediates TF regulation by AHR. STUB1 destabilizes and ubiquitinates TF and mediates TF regulation by.

Fig. 1. Drug combination screen identifies BETi as acting synergistically with PARPi. Drug combination screen identifies BETi as acting synergistically.

Fig. 1. Map showing the study catchment area in the East of England.

Fig. 3. β-AR signaling induces IL-6 in NSCLC cells via activation of PKC and CREB. β-AR signaling induces IL-6 in NSCLC cells via activation of PKC and.

Fig. 2 Fas controls IL-1RA–sEV secretion in murine MSCs.

Downregulation of SPRY4 expression is associated with FGFR1–FRS2 activation. Downregulation of SPRY4 expression is associated with FGFR1–FRS2 activation.

Akt inhibition with AZD5363 does not enhance the radiosensitivity of tumour cells in vitro Akt inhibition with AZD5363 does not enhance the radiosensitivity.

Regulated P124SMEK1 expression cannot alter p-ERK levels or sensitivity to BRAF or MEK inhibition in V600EBRAF melanoma cell lines. Regulated P124SMEK1.

Fig. 5. Nutlin-3 treatment rescues the proliferation and differentiation of NPCs in vitro. Nutlin-3 treatment rescues the proliferation and differentiation.

Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK inhibitors. Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK.

Fig. 4. The effect of single-dose rozanolixizumab on the concentration of IgG subtypes in healthy subjects. The effect of single-dose rozanolixizumab on.

Fig. 6. Analysis of SHIV-325c V1V2 envelope sequences in breakthrough infections. Analysis of SHIV-325c V1V2 envelope sequences in breakthrough infections.

Leto et al., Supplementary Figure S3

Fig. 3. HECTD2 contains a naturally occurring polymorphism at A19, which mislocalizes to the cytosol. HECTD2 contains a naturally occurring polymorphism.

Fig. 2. Cellular response to FolamiRs in vitro.

Fig. 1 LB100 and LB102 specifically inhibit PP2A phosphatase activity and the growth of BCR-ABL+ cells. LB100 and LB102 specifically inhibit PP2A phosphatase.

Fig. 4. Clearance of 12-mer-1 from a nonhuman primate model.

Fig. 4 ALRN-6924 inhibits cellular proliferation and clonogenic capacity, and induces cell cycle arrest and apoptosis in AML cell lines. ALRN-6924 inhibits.

Fig. 2. BET inhibition enhances PARPi-induced DNA damage.

Pharmacologic inhibition of eIF5A hypusination sensitizes KRas-driven tumor cells to MEK and KRas inhibition. Pharmacologic inhibition of eIF5A hypusination.

ONC201 activates the ATF4 pathway through the eIF2α kinases HRI and PKR. ONC201 activates the ATF4 pathway through the eIF2α kinases HRI and PKR. (A) Western.

Fig. 8. Zbtb7a deficiency impairs antigen presentation by AMs.

Differentiation of AZD4785 from MAPK pathway inhibitors in vitro

Fig. 3. Inactivation of the Wnt/β-catenin signaling pathway inhibited cell proliferation and induced apoptosis in A549 and SPC-A-1 cells. Inactivation.

Fig. 5. Mutant KRAS increases HR capacity and MEKi decreases HR capacity in RAS mutant cells, causing increased DNA damage. Mutant KRAS increases HR capacity.

Fig. 1. Potent and selective down-regulation of KRAS mRNA and protein by AZD4785 in vitro and in vivo. Potent and selective down-regulation of KRAS mRNA.

Identification of NSC as a FADD-kinase inhibitor.

Sensor siRNAs can be used in high-order combinations.

Fig. 8 C9orf72 knockdown results in an increase in autophagic flux.

MiR-200c is a PI3K–AKT signaling pathway regulator in CRC

PD and efficacy of AZD4785 in KRAS mutant lung cancer xenograft models

Per1 inhibits growth and induces apoptosis in prostate cancer cell lines. Per1 inhibits growth and induces apoptosis in prostate cancer cell lines. LNCaP,

Changes in signal transduction pathway induced by gefitinib.

The Ser124 site of Cdc25A is required for Cdc25A degradation in response to I3C induction. The Ser124 site of Cdc25A is required for Cdc25A degradation.

FGFR1 is dominantly expressed in mesenchymal-like KRAS-mutant lung cancer cell lines. FGFR1 is dominantly expressed in mesenchymal-like KRAS-mutant lung.

Fig. 5 C9orf72 knockdown disrupts autophagy induction.

Differential effects of the RAF inhibitor PLX4032 in BRAF-mutant melanoma, thyroid, and colorectal cancer cell lines. Differential effects of the RAF inhibitor.

Fig. 2 Increasing KLF17, CDH1, and LASS2 expression reduced malignant progression and promoted apoptosis of tumor cells. Increasing KLF17, CDH1, and LASS2.

Fig. 6 The C9ORF72/SMCR8 complex regulates ULK1.

BEZ235 induces accelerated senescence after radiation (IR) in vitro.

I3C reduces the level of Cdc25A protein in breast cancer cells.

PD and efficacy of AZD4785 in a KRAS wild-type lung cancer PDX model

Presentation transcript:

Fig. 2. Effects of AZD4785 on proliferation and MAPK pathway signaling in KRAS mutant and wild-type cancer cells in vitro. Effects of AZD4785 on proliferation and MAPK pathway signaling in KRAS mutant and wild-type cancer cells in vitro. (A) Correlation between IC50 of KRAS down-regulation and inhibition of colony formation by AZD4785 in KRAS wild-type and mutant cell lines. NCI-H1299, NCI-H1793, and Colo201 have an IC50 of colony formation inhibition by AZD4785 of >10 μM. (B) Correlation between IC50 of KRAS and DUSP6 down-regulation by AZD4785 in KRAS wild-type and mutant cell lines. NCI-H1437, NCI-H1299, and Colo201 have an IC50 of DUSP6 down-regulation by AZD4785 of >10 μM. Mean IC50 is shown and generated from a minimum of two independent experiments. (C) Western blot analysis of cell lysates from NCI-H358 or PC9 cells after treatment for 72 hours with a range of doses of AZD4785. Sarah J. Ross et al., Sci Transl Med 2017;9:eaal5253 Published by AAAS